Aminopeptidase N (CD13) as a target for cancer chemotherapy.
about
Zinc and zinc transporters in prostate carcinogenesisStructural Bases of Coronavirus Attachment to Host Aminopeptidase N and Its Inhibition by Neutralizing AntibodiesSelecting Targets for Tumor Imaging: An Overview of Cancer-Associated Membrane ProteinsPotential therapeutic impact of CD13 expression in non-small cell lung cancerAllosteric inhibition of aminopeptidase N functions related to tumor growth and virus infection.Development of Synthetic Aminopeptidase N/CD13 Inhibitors to Overcome Cancer Metastasis and Angiogenesis.A preliminary study on the interaction between Asn-Gly-Arg (NGR)-modified multifunctional nanoparticles and vascular epithelial cellsThe Rational Design of Therapeutic Peptides for Aminopeptidase N using a Substrate-Based Approach.Dual-targeted peptide-conjugated multifunctional fluorescent probe with AIEgen for efficient nucleus-specific imaging and long-term tracing of cancer cellsIn vitro and in vivo antitumor activity of a novel alkylating agent, melphalan-flufenamide, against multiple myeloma cells.An integrated approach to the ligand binding specificity of Neisseria meningitidis M1 alanine aminopeptidase by fluorogenic substrate profiling, inhibitory studies and molecular modeling.Targeting CD13 (aminopeptidase-N) in turn downregulates ADAM17 by internalization in acute myeloid leukaemia cells.First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies.Melphalan-flufenamide is cytotoxic and potentiates treatment with chemotherapy and the Src inhibitor dasatinib in urothelial carcinoma.Structure-guided, single-point modifications in the phosphinic dipeptide structure yield highly potent and selective inhibitors of neutral aminopeptidases.Dipeptidyl-peptidase IV activity is correlated with colorectal cancer prognosis.Proteomic analysis of media from lung cancer cells reveals role of 14-3-3 proteins in cachexia.Synthesis and evaluation of novel Tc-99m labeled probestin conjugates for imaging APN/CD13 expression in vivo.Altered Activity and Expression of Cytosolic Peptidases in Colorectal CancerEngineered production of cancer targeting peptide (CTP)-containing C-1027 in Streptomyces globisporus and biological evaluationIdentification of alanyl aminopeptidase (CD13) as a surface marker for isolation of mature gastric zymogenic chief cells.pHLIP-mediated targeting of truncated tissue factor to tumor vessels causes vascular occlusion and impairs tumor growthTargeted antitumor prodrug therapy using CNGRC-yCD fusion protein in combination with 5-fluorocytosine.In vitro and in vivo activity of melflufen (J1)in lymphomaA structural insight into the P1S1 binding mode of diaminoethylphosphonic and phosphinic acids, selective inhibitors of alanine aminopeptidases.A SPR biosensor based on signal amplification using antibody-QD conjugates for quantitative determination of multiple tumor markers.Prolyl endopeptidase activity is correlated with colorectal cancer prognosis.Preclinical activity of melflufen (J1) in ovarian cancer.In vitro and in vivo anti-leukemic activity of the peptidase-potentiated alkylator melflufen in acute myeloid leukemia.Tosedostat for the treatment of relapsed and refractory acute myeloid leukemia.Positioning of aminopeptidase inhibitors in next generation cancer therapy.Urinary proteomics and molecular determinants of chronic kidney disease: possible link to proteases.Cell surface markers of cancer stem cells: diagnostic macromolecules and targets for drug delivery.Metabolomic profiling for the identification of novel diagnostic markers in prostate cancer.Second line treatment options for pancreatic cancer.Efficient targeting of CD13 on cancer cells by the immunotoxin scFv13-ETA' and the bispecific scFv [13xds16].Substrate Activity Screening (SAS) and Related Approaches in Medicinal Chemistry.Antitumor activity of opiorphin, sialorphin and their conjugates with a peptide klaklakklaklak.Evaluation of 68Ga-labeled iNGR peptide with tumor-penetrating motif for microPET imaging of CD13-positive tumor xenografts.A CD13 inhibitor, ubenimex, synergistically enhances the effects of anticancer drugs in hepatocellular carcinoma.
P2860
Q27010040-44E70501-F9DB-4165-80D4-B62E7CA1BE2DQ27671374-8E337ABF-6D6C-4A6F-B3B8-EB3293A5D6C0Q28077999-20054140-8A6C-4928-AC69-08AC18F9DE5CQ30313110-E12417B6-ED4F-465F-9101-D380C56A7480Q30844668-EE898DA9-FB51-40D3-964F-D0BB3242B6C7Q33630608-1664231C-8A49-4BAC-B7DD-B308CF3AFDA5Q33682897-5AA57E4E-3760-41D8-B677-2C4AAE43E7A2Q33683970-014600FA-04FB-4F3D-9E56-A5D4B9EDCB87Q33800277-293FCC69-1C85-4C67-A74C-128A3BF45A69Q33902726-2C4ADEA6-031D-4C72-BDB6-97986CAC63FBQ34468476-427956CE-41EB-4497-92DA-05002098A828Q34483504-8503B701-D6F4-4CFE-8399-A34CD6AE6406Q34501199-AFD29EF9-AD57-4924-AE90-E1928E555BD2Q34511534-820B01DC-17D8-4867-A309-238A92C12080Q35090932-A9ECF8F6-07F7-4A6C-8EEF-47636FF68A30Q35195876-70933A1B-1246-4292-AA0F-A8E5B6A66719Q35545361-9EFAAC20-B7EF-4B27-8271-611B59E34ED6Q35681062-E9D79D7C-A22A-466E-9B49-898F08F5E75EQ35739764-743175BA-4726-48DE-959D-EDA476B57E69Q35994054-79EBDF73-C1A7-4488-8683-046E3A682060Q36382069-B6AF69F8-15A8-4673-B5AE-9D72878734BBQ36414221-874BE6AC-7233-4B55-931F-03981F824697Q36493746-E38C01BA-A3B4-449E-A7D9-FCBC1589E298Q36765319-9D8C66CE-3D0A-44D5-9AE9-27D83F82054CQ36902177-7F274154-6DB4-4031-A4E8-74C1F5220193Q37247888-E05FF072-E3DB-482C-8DF6-C3419EEA9C73Q37488703-EE58660A-4ED2-4C7D-BBC2-33732EB3A64CQ37644866-A1A48B0C-6DDC-40D6-B3C4-F0B8D0BCCFE5Q37701604-D4F5C0EF-9D6B-43B8-937E-BFDEE439A2E5Q38169200-905EBCF0-5394-483D-96A5-087A7AE6566AQ38175346-AD392525-98F6-4CBB-9D2E-4C52ABCC69D7Q38222628-F2A90479-8736-4A47-B40E-69AECCC77F69Q38383345-573A61F6-C908-4DCF-82B6-3D2484BAB08FQ38547110-C4E1F86C-F419-4BC1-B4DC-DABE46E36FB4Q38640398-791009BD-D934-4FCE-AC59-09783B67D35DQ38698179-6D7BB90F-56B5-4305-9C8B-288BD35487B4Q38722942-E1F49506-EFE6-45BF-BE34-341753A5F63AQ38730361-35F1E94D-CBD6-4C85-83B2-A50E95EC1E08Q38737096-FA79C6D3-5E82-473C-A911-11FDC9E8E41EQ38775002-BFEE5EC5-7334-47DD-BECD-CE97C4A43F33
P2860
Aminopeptidase N (CD13) as a target for cancer chemotherapy.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Aminopeptidase N (CD13) as a target for cancer chemotherapy.
@ast
Aminopeptidase N (CD13) as a target for cancer chemotherapy.
@en
type
label
Aminopeptidase N (CD13) as a target for cancer chemotherapy.
@ast
Aminopeptidase N (CD13) as a target for cancer chemotherapy.
@en
prefLabel
Aminopeptidase N (CD13) as a target for cancer chemotherapy.
@ast
Aminopeptidase N (CD13) as a target for cancer chemotherapy.
@en
P2860
P50
P1433
P1476
Aminopeptidase N (CD13) as a target for cancer chemotherapy.
@en
P2093
Joachim Gullbo
P2860
P304
P356
10.1111/J.1349-7006.2010.01826.X
P577
2011-01-30T00:00:00Z